MDT

88.02

+0.36%↑

120.93

+3.42%↑

VEEV

157.02

-0.17%↓

HQY

80.21

+0.54%↑

TLRY

6.89

+2.53%↑

MDT

88.02

+0.36%↑

120.93

+3.42%↑

VEEV

157.02

-0.17%↓

HQY

80.21

+0.54%↑

TLRY

6.89

+2.53%↑

MDT

88.02

+0.36%↑

120.93

+3.42%↑

VEEV

157.02

-0.17%↓

HQY

80.21

+0.54%↑

TLRY

6.89

+2.53%↑

MDT

88.02

+0.36%↑

120.93

+3.42%↑

VEEV

157.02

-0.17%↓

HQY

80.21

+0.54%↑

TLRY

6.89

+2.53%↑

MDT

88.02

+0.36%↑

120.93

+3.42%↑

VEEV

157.02

-0.17%↓

HQY

80.21

+0.54%↑

TLRY

6.89

+2.53%↑

Strona główna・Stock List・AnaptysBio Inc

AnaptysBio Inc

Open

SectorHealthcare

70.52 1.15

Buy Sell

Overview

Share price change

24h

Current

Min

65.65

Max

Key metrics
By Trading Economics
Income	35M 50M
Sales	32M 108M
Profit margin	45.833
Employees	104
EBITDA	29M 68M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+18.72% upside

Dividends
By Dow Jones
Next Earnings	1 maj 2026

Market Stats
By TradingEconomics
Market Cap	259M 1.8B
Previous open	69.37
Previous close	70.52

News Sentiment

By Acuity

23%

77%

51 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

19.25 / 21.135 Support & Resistance

AnaptysBio Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

13 kwi 2026, 23:25 UTC

Major News Events

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy -- Update

13 kwi 2026, 22:45 UTC

Major News Events

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy

13 kwi 2026, 18:03 UTC

Earnings

Louis Vuitton Owner Logs Weak Sales as Middle East War Takes Toll -- 2nd Update

13 kwi 2026, 23:58 UTC

Earnings

Review & Preview: Earnings Time -- Barrons.com

13 kwi 2026, 23:49 UTC

Market Talk

Nikkei May Rise After Overnight Gains on Wall Street -- Market Talk

13 kwi 2026, 23:33 UTC

Market Talk

Major News Events

Gold Edges Higher Amid Dollar Weakness -- Market Talk

13 kwi 2026, 23:20 UTC

Market Talk

Uranium Stocks Seen Benefiting From Energy Security Concerns -- Market Talk

13 kwi 2026, 23:01 UTC

Earnings

Aura: Capex Guidance Revised From $111M and $130M to New Range of $262M and $314M >AURA33.SA.BR

13 kwi 2026, 23:01 UTC

Earnings

Aura Minerals: Announces Update to Capex Guidance Including Construction of the Era Dorada Project

13 kwi 2026, 23:01 UTC

Earnings

Aura: Will Update Cap Expenditure Guidance to Include the Project's Construction Phase >AURA33.SA.BR

13 kwi 2026, 22:21 UTC

Acquisitions, Mergers, Takeovers

Chevron Swaps Offshore Gas Stakes to Boost Venezuelan Heavy-Oil Footprint -- Update

13 kwi 2026, 21:53 UTC

Earnings

MarketWise, Inc.: Affirms FY 2026 Guidance, Including Div Target to Class A Hldrs of $1.80 per Shr

13 kwi 2026, 21:53 UTC

Earnings

MarketWise, Inc.: Paid Subscribers Were 381,000 at March 31 Compared to 374,000 at Dec 31, 2025, Active Free Subscribers Were 2.0M at March 31 >MKTW

13 kwi 2026, 21:53 UTC

Earnings

MarketWise, Inc.: 1Q Billings Increased Approximately 15% Yr-over-Yr to Approximately $81M

13 kwi 2026, 21:53 UTC

Earnings

MarketWise, Inc.: Preliminary Selected Unaudited 1Q Paid Subscribers Returning to Growth

13 kwi 2026, 21:26 UTC

Major News Events

U.S. Oil Blockade Is Set to Boost American Exports -- and Prices at the Pump -- WSJ

13 kwi 2026, 21:23 UTC

Earnings

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

13 kwi 2026, 21:16 UTC

Earnings

Goldman Sachs Reports Record Quarter in Banking and Trading -- 4th Update

13 kwi 2026, 20:50 UTC

Market Talk

Major News Events

Basic Materials Roundup: Market Talk

13 kwi 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

13 kwi 2026, 20:34 UTC

Earnings

Victory Capital: 1Q Long-Term AUM Net Flows of -$457M >VCTR

13 kwi 2026, 20:34 UTC

Earnings

Victory Capital: March Avg Total AUM Was $315.3B, Avg Other Assets $3.2B, Avg Total Client Assets $318.5B >VCTR

13 kwi 2026, 20:34 UTC

Earnings

Victory Capital Holdings, Inc.: Total Assets Under Management of $309.8B, Other Assets $3.3B, Total Client Assets of $313.1B as of March 31 >VCTR

13 kwi 2026, 19:59 UTC

Market Talk

Canada Consumers Sour Prior to Big Energy-Price Jump -- Market Talk

13 kwi 2026, 19:50 UTC

Market Talk

Major News Events

Oil Futures Pull Back From Highs on Hopes for Talks -- Market Talk

13 kwi 2026, 19:27 UTC

Market Talk

Major News Events

Correction to Precious Metals Market Talk on April 9

13 kwi 2026, 19:14 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower on Mild Weather -- Market Talk

13 kwi 2026, 18:59 UTC

Market Talk

Major News Events

Fed's Goolsbee: Don't Be Surprised If Consumer Confidence Sours -- Market Talk

13 kwi 2026, 18:59 UTC

Market Talk

Major News Events

Fed's Goolsbee: Oil Shows People Expect Short Term Conflict in Iran -- Market Talk

13 kwi 2026, 18:43 UTC

Market Talk

Precious Metals Lose Ground as U.S. Blockade in Hormuz Gets Underway -- Market Talk

Peer Comparison

Price change

AnaptysBio Inc Forecast

Price Target

By TipRanks

18.72% upside

12 Months Forecast

Average 83.22 USD 18.72%

High 140 USD

Low 50 USD

Based on 10 Wall Street analysts offering 12 month price targets forAnaptysBio Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Based on 10 analysts giving stock ratings to AnaptysBio Inc - Dist in the past 3 months.

Technical Score

By Trading Central

19.25 / 21.135Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

51 / 348 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.